RBC Capital raised the firm’s price target on BeOne Medicines (ONC) to $349 from $311 and keeps an Outperform rating on the shares. The firm is refreshing its views on the stock following key opinion leader checks, additional diligence, and recent conversations with the management, the analyst tells investors in a research note. Brukinsa will remain a leader in the CLL – chronic lymphocytic leukemia – market, while next-gen/life-cycle plays with sonrotoclax and ‘673 both create a market expansion narrative and preempt questions about a potential patent cliff or IRA impact for Brukinsa, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne announces EC approval of Tevimbra in combination with chemotherapy
- Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
- Beigene’s BG-68501 Study: A Potential Game-Changer in Oncology
- Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers
- BeiGene’s Promising Phase 2 Study on Waldenström Macroglobulinemia